Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 19;10(22):5417.
doi: 10.3390/jcm10225417.

Antibody-Mediated Rejection and Recurrent Primary Disease: Two Main Obstacles in Abdominal Kidney, Liver, and Pancreas Transplants

Tsukasa Nakamura  1 , Takayuki Shirouzu  2
Affiliations
Review

Antibody-Mediated Rejection and Recurrent Primary Disease: Two Main Obstacles in Abdominal Kidney, Liver, and Pancreas Transplants

Tsukasa Nakamura et al. J Clin Med. .

Abstract

The advances in acute phase care have firmly established the practice of organ transplantation in the last several decades. Then, the next issues that loom large in the field of transplantation include antibody-mediated rejection (ABMR) and recurrent primary disease. Acute ABMR is a daunting hurdle in the performance of organ transplantation. The recent progress in desensitization and preoperative monitoring of donor-specific antibodies enables us to increase positive outcomes. However, chronic active ABMR is one of the most significant problems we currently face. On the other hand, recurrent primary disease is problematic for many recipients. Notably, some recipients, unfortunately, lost their vital organs due to this recurrence. Although some progress has been achieved in these two areas, many other factors remain largely obscure. In this review, these two topics will be discussed in light of recent discoveries.

Keywords: antibody-mediated rejection; liver transplantation; pancreas transplantation; recurrent primary disease; renal transplantation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Wiebe C., Gibson I.W., Blydt-Hansen T.D., Karpinski M., Ho J., Storsley L.J., Goldberg A., Birk P.E., Rush D.N., Nickerson P.W. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am. J. Transplant. 2012;12:1157–1167. doi: 10.1111/j.1600-6143.2012.04013.x. - DOI - PubMed
    1. Nakamura T., Shirouzu T., Nakata K., Yoshimura N., Ushigome H. The Role of Major Histocompatibility Complex in Organ Transplantation-Donor Specific Anti-Major Histocompatibility Complex Antibodies Analysis Goes to the Next Stage. Int. J. Mol. Sci. 2019;20:4544. doi: 10.3390/ijms20184544. - DOI - PMC - PubMed
    1. Nakamura T., Ushigome H., Watabe K., Imanishi Y., Masuda K., Matsuyama T., Harada S., Koshino K., Iida T., Nobori S., et al. Graft Immunocomplex Capture Fluorescence Analysis to Detect Donor-Specific Antibodies and HLA Antigen Complexes in the Allograft. Immunol. Investig. 2017;46:295–304. doi: 10.1080/08820139.2016.1258711. - DOI - PubMed
    1. Solez K., Axelsen R.A., Benediktsson H., Burdick J.F., Cohen A.H., Colvin R.B., Croker B.P., Droz D., Dunnill M.S., Halloran P.F., et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int. 1993;44:411–422. doi: 10.1038/ki.1993.259. - DOI - PubMed
    1. Racusen L.C., Colvin R.B., Solez K., Mihatsch M.J., Halloran P.F., Campbell P.M., Cecka M.J., Cosyns J.P., Demetris A.J., Fishbein M.C., et al. Antibody-mediated rejection criteria—An addition to the Banff 97 classification of renal allograft rejection. Am. J. Transplant. 2003;3:708–714. doi: 10.1034/j.1600-6143.2003.00072.x. - DOI - PubMed

LinkOut - more resources